首站-论文投稿智能助手
典型文献
It is time to update the ARDS definition: It starts with COVID-19-induced respiratory failure ☆
文献摘要:
Coronavirus disease 2019 (COVID-19) may rapidly worsen respiratory failure, thereby leading to death. COVID-19-induced respiratory failure exhibits some atypical characteristics, silent hypoxemia, and high lung compliance. Some histopathological changes associated with COVID-19-induced respiratory failure differ from those of classic acute respiratory distress syndrome (ARDS). However, compared with classical ARDS, COVID-19-induced respiratory failure has a similar timing of onset, clinical syndromes, radiological profile, and mortality rate in the intensive care unit (ICU). Respiratory failure induced by COVID-19 is a type of ARDS and is currently underdiagnosed. This condition stretches the definition of classic ARDS; therefore, an updated definition is warranted.
文献关键词:
COVID-19;Acute respiratory distress syndrome;Respiratory failure;Silent hypoxemia;Histopathological changes
作者姓名:
Pan Chun;Liu Ling;Xie Jianfeng;Qiu Haibo;Yang Yi
作者机构:
Department of Critical Care Medicine, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiang Su 210009, China
引用格式:
[1]Pan Chun;Liu Ling;Xie Jianfeng;Qiu Haibo;Yang Yi-.It is time to update the ARDS definition: It starts with COVID-19-induced respiratory failure ☆)[J].重症医学(英文),2022(01):29-31
A类:
failure
B类:
It,ARDS,definition,starts,induced,respiratory,Coronavirus,disease,may,rapidly,worsen,thereby,leading,death,exhibits,some,atypical,characteristics,silent,hypoxemia,high,lung,compliance,Some,histopathological,changes,associated,differ,from,those,acute,distress,However,compared,classical,has,similar,timing,onset,clinical,syndromes,radiological,profile,mortality,rate,intensive,care,unit,ICU,Respiratory,type,currently,underdiagnosed,This,condition,stretches,therefore,updated,warranted,Acute,Silent,Histopathological
AB值:
0.576059
相似文献
Safety and immunogenicity of COVID-19 vaccination among liver transplant recipients in China
Qiu-Ju Tian;Man Xie;Ji-Tao Wang;Yi Wang;Bei Zhang;Jin-Zhen Cai;Xiao-Long Qi;Wei Rao-Division of Hepatology,Liver Disease Center,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Organ Transplantation,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Gastroenterology,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;CHESS-COVID-19 Group,Xingtai People's Hospital,Xingtai 054000,China;Department of Clinical Laboratory,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Immunology,Qingdao University Medical College,Qingdao 266000,China;CHESS Center,Institute of Portal Hypertension,The First Hospital of Lanzhou University,Lanzhou 730000,China
Integrated therapeutic plasma exchange and traditional Chinese medicine treatment in a patient with severe COVID-19:A case report
Chia-Wei Lin;Wei-Chen Hsu;Chien-Lu Lu;Su-Hsing Cheng;Cheng-Pin Chen;Yu-Chang Hou-Department of Chinese Medicine,Taoyuan General Hospital,Taoyuan City 330,Taiwan,China;Department of Nephrology,Taoyuan General Hospital,Taoyuan City 330,Taiwan,China;Department of Infectious Disease,Taoyuan General Hospital,Taoyuan City 330,Taiwan,China;School of Public Health,Taipei Medical University,Taipei City 110,Taiwan.China;Department of Bioscience Technology,Chung Yuan Christian University,Taoyuan City 320,Taiwan,China;School of Chinese Medicine,College of Chinese Medicine,China Medical University,Taichung City 404,Taiwan,China;School of Traditional Chinese Medicine,College of Medicine,Chang Gung University,Taoyuan City 333,Taiwan,China
A trial of arbidol hydrochloride in adults with COVID-19
Zhao Jingya;Zhang Jinnong;Jin Yang;Tang Zhouping;Hu Ke;Sun Hui;Shi Mengmeng;Yang Qingyuan;Gu Peiyu;Guo Hongrong;Li Qi;Zhang Haiying;Li Chenghong;Yang Ming;Xiong Nian;Dong Xuan;Xu Juanjuan;Lin Fan;Wang Tao;Yang Chao;Huang Bo;Zhang Jingyi;Chen Shi;He Qiong;Zhou Min;Qu Jieming-Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Institute of Respiratory Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China;Department of Emergency, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory and Critical Care Medicine, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Respiratory and Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, China;Department of Endocrinology, Union Medical College Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430058, China;Department of Respiratory Medicine, Wuhan Bauhinia Hospital, Wuhan, Hubei 430062, China;Department of Respiratory Medicine, Guanggu Hospital District, The Third Hospital of Wuhan, Wuhan, Hubei 430074, China;Department of Respiratory and Critical Care Medicine, Puren Hospital, Wuhan University of Science and Technology, Wuhan, Hubei 430081, China;Department of Respiratory Medicine, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China;Department of Respiratory Medicine, The Sixth General Hospital of Hubei Province, Wuhan, Hubei 430015, China;Tuberculosis Department of Chengdu Public Health Clinical Medical Center, Chengdu, Sichuan 610066, China;Department of Neurology, Wuhan Red Cross Hospital, Wuhan, Hubei 430015, China;Department of Tuberculosis, Jinyintan Hospital, Wuhan, Hubei 430048, China;Department of Cardiology, The Third People’s Hospital of Hubei Province, Wuhan, Hubei 430030, China
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
Yang Yi;Meng Zhang;Heng Xue;Rong Yu;Yang-Oujie Bao;Yi Kuang;Yue Chai;Wen Ma;Jing Wang;Xiaomeng Shi;Wenzhe Li;Wei Hong;Junhua Li;Elishiba Muturi;Hongping Wei;Joachim Wlodarz;Szczepan Roszak;Xue Qiao;Hang Yang;Min Ye-State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;CAS Key Laboratory of Special Pathogens and Biosafety,Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China;University of Chinese Academy of Sciences,Beijing 100049,China;Faculty of Science and Technology,University of Silesia,Katowice 40-007,Poland;Department of Physical and Quantum Chemistry,Faculty of Chemistry,Wroclaw University of Science and Technology,Wroclaw 50-370,Poland
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
Jia Lu;Qiangling Yin;Rongjuan Pei;Qiu Zhang;Yuanyuan Qu;Yongbing Pan;Lina Sun;Ding Gao;Cuiqin Liang;Jingwen Yang;Wei Wu;Jiandong Li;Zongqiang Cui;Zejun Wang;Xinguo Li;Dexin Li;Shiwen Wang;Kai Duan;Wuxiang Guan;Mifang Lian;Xiaoming Yang-National Engineering Technology Research Center for Combined Vaccines,Wuhan Institute of Biological Products Co.Ltd.,Wuhan,430070,China;State Key Laboratory for Molecular Virology and Genetic Engineering National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,102206,China;Center for Emerging Infectious Diseases,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430071,China;CDC-WIV Joint Research Center for Emerging Diseases and Biosafety,Wuhan,430071,China;Institution of Infectious Diseases,Shenzhen Bay Laboratory,Shenzhen,518107,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。